Применение летрозола в режиме монотерапии или последовательной терапии с тамоксифеном у больных раком молочной железы

1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
2. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.
3. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486–92.
4. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45–53.
5. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–9. [Erratum, Lancet 2002; 360: 1520.]
6. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 108192. [Erratum, N Engl J Med 2004; 351: 2461.]
7. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
8. Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007; 25: 2664–70.
9. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23: 5138–47.
10. Boccardo F. Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer. Nat Clin Pract Oncol 2008; 5: 76–7.
11. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559–70. [Erratum, Lancet 2007; 369: 906.]
12. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006; 7: 991–6. [Erratum, Lancet Oncol 2007; 8: 6.]
13. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Cancer Res 2009; 69 (Suppl. 12): abstract.
14. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–29.
15. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44. [Erratum, Ann Oncol 2007; 18: 1917.]
16. Carlson RW, Brown E, Burstein HJ et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4 (Suppl. 1): S1–S26.
17. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006; 94: 460–4.
18. Punglia RS, Kuntz KM, Winer EP et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005; 23: 5178–87.
19. Giobbie-Hurder A, Price KN, Gelber RD. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 2009; 6: 272–87.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
21. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187–220.
22. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 114154.
23. Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18: 859–67.
24. Wang R, Lagakos SW, Ware JH et al. Statistics in medicine — reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 218994.
25. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793–802.
26. Mamounas EP, Jeong JH, Wickerham DL et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008; 26: 1965–71.
27. Clinical Trials (PDQ). Phase III randomized study of continuous letrozole versus intermittent letrozole in postmenopausal women with hormone receptor-positive, node-positive, early-stage breast cancer after completion of 4 to 6 years of prior adjuvant endocrine therapy. Bethesda, MD: National Cancer Institute. (Accessed July 24, 2009, at http://www.cancer.gov/ clinicaltrials/IBCSG-35-07.)
28. Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer –survival or death? J Clin Oncol 2008; 26: 3073–82.
29. Sabnis GJ, Macedo LF, Goloubeva O et al. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008; 68: 4518–24. CopyrightC 2009 Massachusetts Medical Society.

И.В.Поддубная, И.В.Колядина

Кафедра онкологии РМАПО, Москва